Technology

Peptomyc technology and IP is founded on the knowledge accumulated by Dr. Soucek‘s lab on Omomyc, a dominant-negative Myc mutant that is the most efficacious and safe direct Myc inhibitor to date and that shows great therapeutic promise in a variety -if not all- cancer types. Omomyc was considered a proof of principle for many years, and its application was to be limited to gene therapy. However, Dr. Soucek’s lab has shown that the Omomyc peptide itself displays excellent cell penetrating properties and can efficiently enter cells and exert a strong anti-Myc activity that results in arrest/death of cancer cells. Peptomyc now is developing the Omomyc mini-protein – and improved variants – into clinically viable therapeutics for the treatment of cancer patients.

Relevant publications:

  1. Beaulieu, M.-E.; Castillo, F.; Soucek, L. Cells 2020, 9, 1038. 2020 Apr 22.
  2. Massó-Vallés D. and Soucek L. 2020, 9, 883. 2020 Apr 4.
  3. Daniel Massó-Vallés, Marie-Eve Beaulieu and Laura Soucek. Expert Opin Ther Targets. 2020 Jan 31.
  4. Marie-Eve Beaulieu and Laura Soucek. Mol Cell Oncology. 2019 Jun 20.
  5. Marie-Eve Beaulieu, Toni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, Peter Rahl, Loïka Maltais, Mariano F. Zacarias-Fluck, Sílvia Casacuberta-Serra, Erika Serrano del Pozo, Christopher Fiore, Laia Foradada, Virginia Castillo Cano, Matthew Guenther, Eduardo Romero Sanz, Marta Oteo, Cynthia Tremblay, Génesis Martín, Danny Letourneau, Martin Montagne, Miguel Ángel Morcillo Alonso, Jonathan R. Whitfield, Pierre Lavigne and Laura Soucek. Sci Trans Med. 2019 Mar 20;11(484).
  6. Annibali, D., Whitfield, J.R., Favuzzi, E., Jauset, T., Serrano, E., Cuartas, I., Redondo-Campos, S., Folch, G., Gonzalez-Junca, A., Sodir, N.M., et al. (2014). Nature Communications 5, 4632.
  7. Soucek, L., Whitfield, J.R., Sodir, N.M., Masso-Valles, D., Serrano, E., Karnezis, A.N., Swigart, L.B., and Evan, G.I. (2013). Genes & Development 27, 504-513.
  8. Savino, M., Annibali, D., Carucci, N., Favuzzi, E., Cole, M.D., Evan, G.I., Soucek, L., and Nasi, S. (2011). PloS One 6, e22284.
  9. Sodir, N.M., Swigart, L.B., Karnezis, A.N., Hanahan, D., Evan, G.I., and Soucek, L. (2011). Genes & Development 25, 907-916.
  10. Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S., and Evan, G.I. (2008). Nature 455, 679-683.
  11. Soucek, L., Nasi, S., and Evan, G.I. (2004). Cell Death and Differentiation 11, 1038-1045.
  12. Soucek, L., Jucker, R., Panacchia, L., Ricordy, R., Tato, F., and Nasi, S. (2002). Cancer Research 62, 3507-3510.
  13. Soucek, L., Helmer-Citterich, M., Sacco, A., Jucker, R., Cesareni, G., and Nasi, S. (1998). Oncogene 17, 2463-2472.

Cells